Evidence map›Paper›PMID 38428419›Full record

ArticleCell genomics2024

Genomic evolution shapes prostate cancer disease type.

Dan J Woodcock, Atef Sahli, Ruxandra Teslo, Vinayak Bhandari, Andreas J Gruber, Aleksandra Ziubroniewicz, Gunes Gundem, Yaobo Xu, Adam Butler, Ezequiel Anokian and 27 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell genomics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors at 20 institutions in 7 countries.

Dan J WoodcockNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK; Nuffield Department of Medicine, University of Oxford, Oxford, UK; Big Data Institute, University of Oxford, Oxford, UK.
Atef SahliNuffield Department of Medicine, University of Oxford, Oxford, UK; Big Data Institute, University of Oxford, Oxford, UK.
Ruxandra TesloBig Data Institute, University of Oxford, Oxford, UK.
Vinayak BhandariDepartment of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
Andreas J GruberNuffield Department of Medicine, University of Oxford, Oxford, UK; Big Data Institute, University of Oxford, Oxford, UK; Department of Biology, University of Konstanz, Konstanz, Germany.
Aleksandra ZiubroniewiczNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK; Big Data Institute, University of Oxford, Oxford, UK.
Gunes GundemCancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK; Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Yaobo XuCancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
Adam ButlerCancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK.
Ezequiel AnokianThe Institute of Cancer Research, London, UK.
Bernard J PopeMelbourne Bioinformatics, University of Melbourne, Melbourne, VIC, Australia; Department of Clinical Pathology, The University of Melbourne, Melbourne, VIC, Australia; Department of Medicine, Central Clinical School, Monash University, Melbourne, VIC, Australia.
Chol-Hee JungMelbourne Bioinformatics, University of Melbourne, Melbourne, VIC, Australia.
Maxime TarabichiThe Francis Crick Institute, London, UK; Institute of Interdisciplinary Research (IRIBHM), Universite Libre de Bruxelles, Brussels, Belgium.
Stefan C DentroNuffield Department of Medicine, University of Oxford, Oxford, UK; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK; The Francis Crick Institute, London, UK.
J Henry R FarmeryStatistics and Computational Biology Laboratory, Cancer Research UK Cambridge Institute, Cambridge, UK.
CRUK ICGC Prostate Group
Peter Van LooThe Francis Crick Institute, London, UK; Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Anne Y WarrenDepartment of Histopathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Vincent GnanapragasamCambridge Urology Translational Research and Clinical Trials Office, Addenbrooke's Hospital, Cambridge, UK; Division of Urology, Department of Surgery, University of Cambridge, Cambridge, UK; Department of Urology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Freddie C HamdyNuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
G Steven BovaProstate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland; Tays Cancer Center, Tampere University Hospital, Tampere, Finland.
Christopher S FosterHCA Laboratories, London, UK.
David E NealUro-Oncology Research Group, Cancer Research UK Cambridge Institute, Cambridge, UK; Department of Surgical Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
Yong-Jie LuCentre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.
Zsofia Kote-JaraiThe Institute of Cancer Research, London, UK.
Michael FraserDepartment of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
Robert G BristowDepartment of Medical Biophysics, University of Toronto, Toronto, ON, Canada; Division of Cancer Sciences, Faculty of Biology, Health and Medicine, University of Manchester, Manchester, UK; The Christie NHS Foundation Trust, Manchester, UK; CRUK Manchester Institute, University of Manchester, Manchester, UK; Manchester Cancer Research Centre, University of Manchester, Manchester, UK.
Paul C BoutrosDepartment of Medical Biophysics, University of Toronto, Toronto, ON, Canada; Departments of Human Genetics and Urology, University of California, Los Angeles, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA.
Anthony J CostelloDepartment of Surgery, University of Melbourne, Melbourne, VIC, Australia; Department of Urology, Royal Melbourne Hospital, Melbourne, VIC, Australia; Victorian Comprehensive Cancer Centre, Parkville, VIC, Australia.
Niall M CorcoranDepartment of Surgery, University of Melbourne, Melbourne, VIC, Australia; Department of Urology, Royal Melbourne Hospital, Melbourne, VIC, Australia; Victorian Comprehensive Cancer Centre, Parkville, VIC, Australia.
Christopher M HovensDepartment of Surgery, University of Melbourne, Melbourne, VIC, Australia; Department of Urology, Royal Melbourne Hospital, Melbourne, VIC, Australia; Victorian Comprehensive Cancer Centre, Parkville, VIC, Australia.
Charlie E MassieUro-Oncology Research Group, Cancer Research UK Cambridge Institute, Cambridge, UK; Early Detection Programme and Urological Malignancies Programme, Cancer Research UK Cambridge Centre, Department of Oncology, University of Cambridge, Cambridge, UK.
Andy G LynchStatistics and Computational Biology Laboratory, Cancer Research UK Cambridge Institute, Cambridge, UK; School of Medicine/School of Mathematics and Statistics, University of St Andrews, St Andrews, UK.
Daniel S BrewerNorwich Medical School, University of East Anglia, Norwich, UK; Earlham Institute, Norwich, UK. Electronic address: d.brewer@uea.ac.uk.
Rosalind A EelesThe Institute of Cancer Research, London, UK; Royal Marsden NHS Foundation Trust, London, UK. Electronic address: ros.eeles@icr.ac.uk.
Colin S CooperThe Institute of Cancer Research, London, UK; Norwich Medical School, University of East Anglia, Norwich, UK. Electronic address: colin.cooper@uea.ac.uk.
David C WedgeNuffield Department of Medicine, University of Oxford, Oxford, UK; Big Data Institute, University of Oxford, Oxford, UK; Manchester Cancer Research Centre, University of Manchester, Manchester, UK; Oxford NIHR Biomedical Research Centre, Oxford, UK; Manchester NIHR Biomedical Research Centre, Manchester, UK. Electronic address: david.wedge@manchester.ac.uk.
University of Oxford · GBInstitute of Cancer Research · GBAddenbrooke's Hospital · GBCancer Research UK · GBUniversity of Melbourne · AUUniversity of Toronto · CAWellcome Sanger Institute · GBCambridge University Hospitals NHS Foundation Trust · GBCancer Research UK Cambridge Center · GBEarlham Institute · GBMemorial Sloan Kettering Cancer Center · USMonash University · AUOpen Data Institute · GBQueen Mary University of London · GBTampere University Hospital · FIThe Christie NHS Foundation Trust · GBThe Francis Crick Institute · GBThe Royal Melbourne Hospital · AUThe University of Texas MD Anderson Cancer Center · USUniversité Libre de Bruxelles · BE

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016042Wellcome Trust CC2008
6 · The paper itself

Abstract

The development of cancer is an evolutionary process involving the sequential acquisition of genetic alterations that disrupt normal biological processes, enabling tumor cells to rapidly proliferate and eventually invade and metastasize to other tissues. We investigated the genomic evolution of prostate cancer through the application of three separate classification methods, each designed to investigate a different aspect of tumor evolution. Integrating the results revealed the existence of two distinct types of prostate cancer that arise from divergent evolutionary trajectories, designated as the Canonical and Alternative evolutionary disease types. We therefore propose the evotype model for prostate cancer evolution wherein Alternative-evotype tumors diverge from those of the Canonical-evotype through the stochastic accumulation of genetic alterations associated with disruptions to androgen receptor DNA binding. Our model unifies many previous molecular observations, providing a powerful new framework to investigate prostate cancer disease progression.

Indexed as

Prostatic NeoplasmsEvolution, MolecularGenomicsHumansMaleMutationProstateAR bindingcancer evolutionevotype modelevotypesorderingprostate cancer

Identifiers

PMID38428419
PMCPMC10943594
OpenAlexW4392302540

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.